Home Cart Sign in  
Chemical Structure| 42521-82-4 Chemical Structure| 42521-82-4

Structure of IPA-3
CAS No.: 42521-82-4

Chemical Structure| 42521-82-4

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

IPA-3 is a selective non-ATP competitive PAK1 inhibitor with an IC50 of 2.5 μM, and it shows no inhibition to group II PAKs (PAKs 4-6).

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of IPA-3

CAS No. :42521-82-4
Formula : C20H14O2S2
M.W : 350.45
SMILES Code : OC1=CC=C2C=CC=CC2=C1SSC3=C4C=CC=CC4=CC=C3O
MDL No. :MFCD00388917
InChI Key :RFAXLXKIAKIUDT-UHFFFAOYSA-N
Pubchem ID :521106

Safety of IPA-3

GHS Pictogram:
Signal Word:Danger
Hazard Statements:H318-H410
Precautionary Statements:P273-P280-P305+P351+P338-P501
Class:9
UN#:3077
Packing Group:

Related Pathways of IPA-3

cytoskeleton

Isoform Comparison

Biological Activity

Target
  • PAK

    PAK1, IC50:2.5 μM

  • PAK1

    PAK1, IC50:2.5 μM

In Vitro:

Cell Line
Concentration Treated Time Description References
OA chondrocytes 10 μM 3 days To evaluate the effects of IPA-3 on OA chondrocytes, results showed that 10 μM IPA-3 had no significant effect on cell viability, reduced PAK2 phosphorylation levels, increased the expression of cartilage-specific genes, and decreased the expression of hypertrophy-related genes. PMC6802609
HCC827 50 μM 6 h Inhibited cell viability and colony formation, and downregulated the expression and phosphorylation of multiple signaling pathway proteins related to lung cancer PMC6819333
C2C12 10 μM 24 h To investigate the effect of IPA-3 on C2C12 cell differentiation, results showed that IPA-3 treatment reduced p38 phosphorylation in C2C12 cells, affecting their differentiation. PMC6104114
Mesoangioblasts (Mabs) 10 μM 9 days To investigate the effect of IPA-3 on Mabs cell differentiation, results showed that IPA-3 treatment reduced p38 phosphorylation in Mabs cells, affecting their differentiation. PMC6104114
Satellite cells (SCs) 10 μM 6 days To investigate the effect of IPA-3 on satellite cell differentiation, results showed that IPA-3 treatment reduced MyHC expression in satellite cells, affecting their terminal differentiation. PMC6104114
Alexander HCC cells 2.5 μM 20 minutes IPA-3 blocked the endocytosis of both extracellular tracers induced by the GSK3 inhibitor CHIR99021 PMC7666578
RM1 cells 10, 20, 30 μM 24 hours IPA-3 significantly decreased the proliferation of RM1 cells and inhibited their migration. PMC7414983
KYSE30 cells 12.81 μM 48 hours IPA-3 significantly inhibited the growth of KYSE30 cells PMC6458688
KYSE150 cells 13.94 μM 48 hours IPA-3 significantly inhibited the growth of KYSE150 cells PMC6458688

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice PLPP/CIN−/− and PLPP/CINTg mice Intraperitoneal injection 5 μM Every 2 days for 30 days IPA-3 shortened the latency of KA-induced seizure onset without affecting seizure severity and ameliorated KA-induced CA3 neuronal death. PMC10141957
Nude mice HCC827, H23, H520 cell line xenograft models Intraperitoneal injection or oral gavage 10 mg/kg Once daily for 7 days IPA-3 in combination with auranofin significantly inhibited tumor volume and weight growth PMC6819333
Mice CTX-induced muscle injury Intraperitoneal injection 3.5 mg/kg Single dose, lasting 2 hours To investigate the effect of IPA-3 on muscle regeneration, results showed that IPA-3 treatment delayed muscle regeneration, increased the fraction of centrally nucleated fibers, and reduced muscle cross-sectional area. PMC6104114
C57BL/6 mice lung metastasis model intraperitoneal injection 10 mg/kg Once daily for 2 or 4 weeks IPA-3 significantly reduced the number of lung nodules, indicating its inhibitory effect on lung metastasis. PMC7414983
Nude mice Subcutaneous tumor model Intraperitoneal injection 4 mg/kg 2 days before, 0 day, 3 days, and 7 days IPA-3 significantly inhibited tumor growth and lung metastasis of KYSE150 cells PMC6458688

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.85mL

0.57mL

0.29mL

14.27mL

2.85mL

1.43mL

28.53mL

5.71mL

2.85mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories